Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
International Journal of Hematology
Erschienen in: International Journal of Hematology 5/2017

29.03.2017 | Progress in Hematology

Leukemic stem cells: identification and clinical application

verfasst von: Diana Hanekamp, Jacqueline Cloos, Gerrit Jan Schuurhuis

Erschienen in: International Journal of Hematology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Leukemic stem cells (LSCs) in acute myeloid leukemia (AML) represent a low-frequency subpopulation of leukemia cells that possess stem cell properties distinct from the bulk leukemia cells, including self-renewal capacity and drug resistance. Due to these properties, LSCs are supposed to facilitate the development of relapse. The existence of LSCs is demonstrated by the ability to engraft and initiate human AML in immune-compromised mouse models. Although several lines of evidence suggest the complex heterogeneity of phenotypes displayed by LSC, many studies consider the CD34+/CD38− compartment as the most relevant. To increase the understanding of the true LSC, techniques such as multicolor flow cytometry, side-population assay and ALDH assay are utilized in many laboratories and could aid in this. A better understanding of different LSC phenotypes is necessary to enhance risk group classification, guide clinical decision-making and to identify new therapeutic targets. These efforts to eliminate LSC should ultimately improve the dismal AML outcome by preventing relapse development.
Literatur
1.
Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med. 2009;15:1010–2.CrossRefPubMed
2.
Vormoor J, Lapidot T, Pflumio F, Risdon G, Patterson B, Broxmeyer HE, et al. Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice. Blood. 1994;83:2489–97.PubMed
3.
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–8.CrossRefPubMed
4.
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–7.CrossRefPubMed
5.
Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One. 2014;9:e107587.CrossRefPubMedPubMedCentral
6.
Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, Scholten WJ, Snel AN, Veldhuizen D, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2016;30:439–46.CrossRefPubMed
7.
Terpstra W, Prins A, Ploemacher RE, Wognum BW, Wagemaker G, Löwenberg B, et al. Long-term leukemia-initiating capacity of a CD34− subpopulation of acute myeloid leukemia. Blood. 1996;87:2187–94.PubMed
8.
Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R γ c-deficient mice. J Clin Investig. 2011;121:384–95.CrossRefPubMed
9.
Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice. Blood. 2005;106:1565–73.CrossRefPubMedPubMedCentral
10.
Eppert K, Takenake K, Lechman ER, Waldron L, Nilsson B, van Galen P, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17:1086–93.CrossRefPubMed
11.
Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, et al. Anti-CD38 antibody mediated clearance of human repopulating cells masks the heterogeneity of leukemia initiating cells anti-CD38 antibody mediated clearance of human repopulating cells masks the heterogeneity of leukemia initiating cells. Blood. 2008;112:568–76.CrossRefPubMed
12.
Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, et al. Leukemia initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34—fraction leukemia initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34 fraction. Blood. 2010;115:1976–85.CrossRefPubMedPubMedCentral
13.
Ng SWK, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540:433–7.CrossRefPubMed
14.
van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11:6520–7.CrossRefPubMed
15.
Costello RT, Mallet F, Gaugler B, Sainty D, Arnoulet C, Gastaut JA, et al. Human acute myeloid leukemia CD34+/CD38− progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res. 2000;60:4403–11.PubMed
16.
Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25:1315–21.CrossRefPubMed
17.
Zeijlemaker W, Meijer R, Kelder A, Ham J, Oussoren-Brockhoff YJM, Snel AN, et al. Manuscript (submitted).
18.
Zeijlemaker W, Kelder A, Wouters R, Valk PJM, Witte BI, Cloos J, et al. Absence of leukaemic CD34+ cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered. Br J Haematol. 2015;171:227–38.CrossRef
19.
Zhu H, Liu Y, Jiang H, Lu J, Qin Y, Jiang Q, et al. CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation. Leuk Res. 2013;37:624–30.CrossRefPubMed
20.
van der Pol MA, Feller N, Roseboom M, Moshaver B, Westra G, Broxterman HJ, et al. Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica. 2003;88:983–93.PubMed
21.
Schuurhuis GJ, Meel MH, Wouters F, Min LA, Terwijn M, de Jonge NA, et al. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS One. 2013;8:e78897.CrossRefPubMedPubMedCentral
22.
Boesch M, Reimer D, Rumpold H, Zeimet AG, Sopper S, Wolf F, et al. DyeCycle violet used for side population detection is a substrate of P-glycoprotein. Cytom Part A. 2012;81A:517–22.CrossRef
23.
Richard V, Nair MG, Santhosh Kumar TR, Pillai MR. Side population cells as prototype of chemoresistant, tumor-initiating cells. Int: Biomed Res; 2013.
24.
Wang Y, Yin C, Feng L, Ma L, Wei Y, Sheng Q. Sorting, identification and enrichment of side population cells in THP-1 acute monocytic leukemia cells. Oncol Rep. 2013;29:1923–31.PubMed
25.
Roshal M, Chien S, Othus M, Wood BL, Fang M, Appelbaum FR, et al. The proportion of CD34(+)CD38(low or neg) myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia. Leukemia. 2013;27:728–31.CrossRefPubMed
26.
Feuring-Buske M, Hogge DE. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34+ CD38− progenitor cells from patients with acute myeloid leukemia. Blood. 2001;97:3882–90.CrossRefPubMed
27.
Wulf GG, Wang R, Kuehnle I, Weidner D, Marini F, Brenner MK, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001;98:1166–73.CrossRefPubMed
28.
Moshaver B, van Rhenen A, Kelder A, van der Pol M, Terwijn M, Bachas C, et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells. 2008;26:3059–67.CrossRefPubMed
29.
Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, et al. A clinically relevant population of leukemic CD34+ CD38− cells in acute myeloid leukemia. Blood. 2012;119:3571–7.CrossRefPubMedPubMedCentral
30.
Hoang VT, Buss EC, Wang W, Hoffmann I, Raffel S, Zepeda-Moreno A, et al. The rarity of ALDH+ cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients. Int J Cancer. 2015;137:525–36.CrossRefPubMedPubMedCentral
31.
Venton G, Pérez-Alea M, Baier C, Fournet G, Quash G, Labiad Y, et al. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors. Blood Cancer J. 2016;6:e469.CrossRefPubMedPubMedCentral
32.
Bachas C, Schuurhuis GJ, Assaraf YG, Kwidama ZJ, Kelder A, Wouters F, et al. The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia. 2012;26:1313–20.CrossRefPubMed
33.
Ho T, LaMere M, Stevens BM, Ashton JM, Myers JR, O’Dwyer KM, et al. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 2016;128:1671–9.CrossRefPubMed
34.
Parkin B, Ouillette P, Li Y, Keller J, Lam C, Roulston D, et al. Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood. 2013;121:369–77.CrossRefPubMedPubMedCentral
35.
Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med. 2016;22:792–9.CrossRefPubMedPubMedCentral
36.
Ding L, Ley TJ, Larson DE, Miller CA, Kobolt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing. Nature. 2012;481:506–10.CrossRefPubMedPubMedCentral
37.
Krӧnke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MWM, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood. 2013;122:100–9.CrossRef
38.
Witte KE, Ahlers J, Schäfer I, André M, Kerst G, Scheel-Walter HG, et al. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. Pediatr Hematol. 2011;28:91–9.CrossRef
39.
Hanekamp DW, Denys B, Kaspers GJL, te Marvelde JG, Schuurhuis GJ, de Haas V, et al. The relevance of stem cell load at diagnosis for the development of relapse in pediatric acute myeloid leukemia. Blood. 2015;126:2584.
40.
41.
Buldini B, Rizzati F, Masetti R, Fagioli F, Menna G, Micalizzi C, et al. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. Br J Haematol. 2017. doi:10.​1111/​bjh.​14523.
42.
Terwijn M, van Putten WLJ, Kelder A, van der Velden VHJ, Brooimans RA, Pabst T, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889–97.CrossRefPubMed
43.
Klco JM, Miller CA, Griffith M, Petti A, Spencer DH, Ketkar-Kulkarni S, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314:811–22.CrossRefPubMedPubMedCentral
44.
Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422–33.CrossRefPubMed
45.
Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013;31:4123–31.CrossRefPubMed
46.
Khan N, Freeman SD, Virgo P, Couzens S, Richardson P, Thomas I, et al. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts. Br J Haematol. 2015;170:80–4.CrossRefPubMed
47.
Estey E, Othus M, Lee SJ, Appelbaum FR, Gale RP. New drug approvals in acute myeloid leukemia: what’s the best end point? Leukemia. 2015;30:521–5.CrossRefPubMedPubMedCentral
48.
Han L, Jorgensen JL, Brooks C, Shi C, Zhang Q, Nogueras GM, et al. Anti-leukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody-conjugate in acute myeloid leukemia. Clin Cancer Res. 2017. doi:10.​1158/​1078-0432.​CCR-16-1904.
49.
Jedema I, Barge RMY, van der Velden VHJ, Nijmeijer BA, van Dongen JJM, Willemze R, et al. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia. 2003;18:316–25.CrossRef
50.
Khan N, Hills RK, Virgo P, Couzens S, Clark N, Gilkes A, et al. Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia. Leukemia. 2016. doi:10.​1038/​leu.​2016.​309.
51.
Jawad M, Seedhouse C, Mony Y, Grundy M, Russell NH, Pallis M. Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia. 2010;24:74–80.CrossRefPubMed
52.
Giles F, Estey E, O’Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer. 2003;98:2095–104.CrossRefPubMed
53.
54.
van Rhenen A, van Dongen GAMS, Kelder A, Rombouts EJ, Feller N, Moshaver B, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110:2659–66.CrossRefPubMed
55.
Darwish NHE, Sudha T, Godugu K, Elbaz O, Abdelghaffar HA, Hassan EEA, et al. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget. 2016;7:57811–20.PubMedPubMedCentral
56.
Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7:708–17.CrossRefPubMed
57.
Kikushige Y, Miyamoto T. Identification of TIM-3 as a leukemic stem cell surface molecule in primary acute myeloid leukemia. Oncology. 2015;89(suppl 1):28–32.CrossRefPubMed
58.
Du W, Hu Y, Lu C, Li J, Liu W, He Y, et al. Cluster of differentiation 96 as a leukemia stem cell-specific marker and a factor for prognosis evaluation in leukemia. Mol Clin Oncol. 2015;3:833–8.PubMedPubMedCentral
59.
Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev. 2012;12:278–87.CrossRef
60.
61.
Wojtuszkiewicz A, Assaraf YG, Maas MJP, Kaspers GJL, Jansen G, Cloos J. Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance. Expert Opin Drug Metab Toxicol. 2015;11:673–89.CrossRefPubMed
62.
Lee SCW, Abdel-Wahab O. Therapeutic targeting of splicing in cancer. Nat Med. 2016;22:976–86.CrossRefPubMed
63.
64.
65.
Sánchez-Aguilera A, Méndez-Ferrer S. The hematopoietic stem-cell niche in health and leukemia. Cell Mol Life Sci. 2017;74:579–90.CrossRefPubMed
66.
Rashidi A, DiPersio JF. Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence. Ther Adv Hematol. 2016;7:40–51.CrossRefPubMedPubMedCentral
67.
Barbieri F, Bajetto A, Thellung S, Würth R, Florio T. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma. Expert Opin Drug Discov. 2016;11:1093–109.CrossRefPubMed
68.
Getta BM, Devlin S, Maloy MA, Mohanty A, Arcila M, Tallman MS, et al. Multicolor flow cytometry and multi-gene next generation sequencing are complimentary and highly predictive for relapse in acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Blood. 2016;128:834.
69.
Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, et al. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A. 2015;87:346–56.CrossRefPubMedPubMedCentral
70.
Askmyr M, Ågerstam H, Hansen N, Gordon S, Arvanitakis A, Rissler M, et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood. 2013;121:3709–13.CrossRefPubMed
71.
Ågerstam H, Karlsson C, Hansen N, Sandén C, Askmyr M, von Palffy S, et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc Natl Acad Sci. 2015;112:10786–91.CrossRefPubMedPubMedCentral
72.
Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012;120:1290–8.CrossRefPubMedPubMedCentral
73.
Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci. 2011;108:5009–14.CrossRefPubMedPubMedCentral
74.
Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells yoriko. Sci Transl Med. 2010;2:179.CrossRef
75.
Ehninger A, Kramer M, Röllig C, Thiede C, Bornhäuser M, von Bonin M, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4:e218.CrossRefPubMedPubMedCentral
76.
Kersten B, Valkering M, Wouters R, van Amerongen R, Hanekamp D, Kwidama Z, et al. CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia. Br J Haematol. 2016;173:219–35.CrossRefPubMed
77.
Ponce LP, Fenn NC, Moritz N, Krupka C, Kozik JH, Lauber K, et al. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells. Oncotarget. 2017;8:11284–301.PubMed
78.
Chung SS, Tavakkoli M, Klimek VM, Park CY. CD99 is a therapeutic target on disease stem cells in acute myeloid leukemia and the myelodysplastic syndromes. Blood. 2014;124:3760.
79.
van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AWM, Zweegman S, et al. Aberrant marker expression patterns on the CD34+ CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia. 2007;21:1700–7.CrossRefPubMed
80.
Harrington KH, Gudgeon CJ, Laszlo GS, Newhall KJ, Sinclair AM, Frankel SR, et al. The broad anti-AML activity of the CD33/CD3 BiTE antibody construct, AMG 330, is impacted by disease stage and risk. PLoS One. 2015;10:1–13.
81.
Sutherland MSK, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122:1455–63.CrossRef
82.
Noordhuis P, Terwijn M, Rutten AP, Smit L, Ossenkoppele GJ, Schuurhuis GJ. Targeting of CLEC12A in acute myeloid leukemia by antibody-drug-conjugates and bispecific CLL-1×CD3 BiTE Antibody. Blood. 2010;116:2890.
83.
Sutherland MSK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, et al. SGN-CD123A, a pyrrolobenzodiazepine dimer linked anti-CD123 antibody drug conjugate, demonstrates effective anti-leukemic activity in multiple preclinical models of AML. Blood. 2015;126:330.
84.
Gadhoum SZ, Madhoun NY, Abuelela AF, Merzaban JS. Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy. Leukemia. 2016;30:2379–401.CrossRef
85.
Blackburn JS, Liu S, Wilder JL, Dobrinski KP, Lobbardi R, Moore FE, et al. Clonal evolution enhances leukemia propagating cell frequency in T-cell acute lymphoblastic leukemia through akt/mtorc1 pathway activation. Cancer Cell. 2014;25:366–78.CrossRefPubMedPubMedCentral
86.
Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, et al. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia. 2008;22:147–60.CrossRefPubMed
87.
Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, et al. apoptosis in AML cells under conditions mimicking the bone marrow microenvironment targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 2012;120:2679–89.CrossRefPubMedPubMedCentral
88.
Zeng Z, Wang Y, Qiu YH, Mak DH, Coombes K, You SY, et al. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells. Oncotarget. 2016;7:55083–97.PubMedPubMedCentral
89.
Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329–41.CrossRefPubMedPubMedCentral
90.
Etchin J, Berezovskaya A, Conway AS, Galinsky IA, Stone RM, Baloglu E, et al. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia. 2017;31:143–50.CrossRefPubMed
91.
Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, et al. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia. 2016;30:190–9.CrossRefPubMed
92.
Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105:4163–9.CrossRefPubMedPubMedCentral
93.
Fukushima N, Minami Y, Kakiuchi S, Kuwatsuka Y, Hayakawa F, Jamieson C, et al. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 2016;107:1422–9.CrossRefPubMedPubMedCentral
94.
van der Helm LH, Bosman MCJ, Schuringa JJ, Vellenga E. Effective targeting of primitive AML CD34+ cells by the second-generation proteasome inhibitor carfilzomib. Br J Haematol. 2015;171:652–5.CrossRefPubMed
95.
Kagoya Y, Yoshimi A, Kataoka K, Nakagawa M, Kumano K, Arai S, et al. Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity. J Clin Investig. 2014;124:528–42.CrossRefPubMedPubMedCentral
96.
Li Y, Chen K, Zhou Y, Xiao Y, Deng M, Jiang Z, et al. A new strategy to target acute myeloid leukemia stem and progenitor cells using chidamide, a histone deacetylase inhibitor. Curr Cancer Drug Targets. 2015;15:493–503.CrossRefPubMed
97.
Rau RE, Rodriguez BA, Luo M, Jeong M, Rosen A, Rogers JH, et al. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 2016;128:971–81.CrossRefPubMedPubMedCentral
98.
Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013;19:357–66.CrossRefPubMed
99.
Hsieh YT, Jiang E, Pham J, Kim HN, Abdel-Azim H, Khazal S, et al. VLA4 blockade in acute myeloid leukemia. Blood. 2013;122:3944.
Metadaten
Titel
Leukemic stem cells: identification and clinical application
verfasst von
Diana Hanekamp
Jacqueline Cloos
Gerrit Jan Schuurhuis
Publikationsdatum
29.03.2017
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 5/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-017-2221-5

Weitere Artikel der Ausgabe 5/2017

International Journal of Hematology 5/2017 Zur Ausgabe

Original Article

Spousal hematopoietic stem cell transplantation

Original Article

Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia

Original Article

A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan

Case Report

Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia

Original Article

Serum concentrations of apoptosis-associated molecules in septic children with leukemia, neutropenia and fever

Original Article

Body mass index is a prognostic factor in adult patients with acute myeloid leukemia

Neu im Fachgebiet Onkologie

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise